Current Neurology and Neuroscience Reports

, Volume 3, Issue 3, pp 223–228 | Cite as

Oligodendrogliomas: An update on basic and clinical research

  • Marc Sanson
  • Lucinda Aguirre-Cruz
  • Stéphanie Cartalat-Carel
  • Khe Hoang-Xuan


Oligodendrogliomas have been the focus of considerable interest over the past decade, ever since they were recognized as chemosensitive tumors. They were once believed to represent less than 5% of gliomas, but by using expanded criteria, they may well represent up to one third. In fact, morphologic criteria are vague and highly subjective and the histologic diagnosis, therefore, remains highly controversial and unsatisfactory. New oligodendrocytic lineage markers, such as OLIG1/2 gene, will probably help to define the real spectrum of oligodendroglial tumors, which may include a wide variety of tumors with very different prognoses. Recently, genetic markers, and particularly loss of 1p and 19q chromosomes, have been shown to predict both prognosis and response to treatment. There is little doubt that these emerging techniques will be very helpful in clinical practice for refining both classification and therapeutic indications of oligodendroglial tumors.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Cairncross JG, MacDonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988, 23:360–364.PubMedCrossRefGoogle Scholar
  2. 2.
    Kleihues P, Louis DN, Scheithauer BW, et al.: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002, 61:215–225.PubMedGoogle Scholar
  3. 3.
    Daumas-Duport C, Varlet P, Tucker ML, et al.: Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neuro-Oncol 1997, 34:37–59.CrossRefGoogle Scholar
  4. 4.
    Burger PC: What is an oligodendroglioma? Brain Pathol 2002, 12:257–259.PubMedCrossRefGoogle Scholar
  5. 5.
    Coons SW, Johnson PC, Scheithauer BW, et al.: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997, 79:1381–1393.PubMedCrossRefGoogle Scholar
  6. 6.
    Daumas-Duport C, Tucker ML, Kolles H, et al.: Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neuro-Oncol 1997, 34:61–78.CrossRefGoogle Scholar
  7. 7.
    Donahue B, Scott CB, Nelson JS, et al.: Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 1997, 38:911–914.PubMedCrossRefGoogle Scholar
  8. 8.
    He J, Mokhtari K, Sanson M, et al.: Glioblastomas with an oligodendroglial componant: a pathological and molecular study. J Neuropathol Exp Neurol 2001, 60:863–871.PubMedGoogle Scholar
  9. 9.
    Pringle NP, Yu WP, Howell M, et al.: Fgfr3 expression by astrocytes and their precursors: evidence that astrocytes and oligodendrocytes originate in distinct neuroepithelial domains. Development 2003, 130:93–102.PubMedCrossRefGoogle Scholar
  10. 10.
    Dai C, Celestino JC, Okada Y, et al.: PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001, 15:1913–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Popko B, Pearl DK, Walker DM, et al.: Molecular markers that identify human astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 2002, 61:329–338.PubMedGoogle Scholar
  12. 12.
    Shoshan Y, Nishiyama A, Chang A, et al.: Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A 1999, 96:10361–10366.PubMedCrossRefGoogle Scholar
  13. 13.
    Lu QR, Yuk D, Alberta JA, et al.: Sonic hedgehog-regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system. Neuron 2000, 25:317–329.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhou Q, Wang S, Anderson DJ: Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors. Neuron 2000, 25:331–343.PubMedCrossRefGoogle Scholar
  15. 15.
    Lu QR, Park JK, Noll E, et al.: Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U SA 2001, 98:10851–10856. OLIG1 and OLIG2, which are both involved in oligodendroglial specification, are expressed by most of the oligodendroglial tumors but not by glioblastomas, and could be useful markers in clinical practice.CrossRefGoogle Scholar
  16. 16.
    Marie Y, Sanson M, Mokhtari K, et al.: OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001, 358:298–300. OLIG1 and OLIG2, which are both involved in oligodendroglial specification, are expressed by most of the oligodendroglial tumors but not by glioblastomas, and could be useful markers in clinical practice.PubMedCrossRefGoogle Scholar
  17. 17.
    Ino Y, Betensky RA, Zlatescu MC, et al.: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001, 7:839–845.PubMedGoogle Scholar
  18. 18.
    Sasaki H, Zlatescu MC, Betensky RA, et al.: Histopathologicalmolecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 2002, 61:58–63.PubMedGoogle Scholar
  19. 19.
    Bello MJ, Leone PE, Vaquero J, et al.: Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995, 64:207–210.PubMedCrossRefGoogle Scholar
  20. 20.
    Smith JS, Alderete B, Minn Y, et al.: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999, 18:4144–4152.PubMedCrossRefGoogle Scholar
  21. 21.
    Husemann K, Wolter M, Buschges R, et al.: Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 1999, 58:1041–1050.PubMedGoogle Scholar
  22. 22.
    Smith JS, Tachibana I, Lee HK, et al.: Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000, 29:16–25.PubMedCrossRefGoogle Scholar
  23. 23.
    Sanson M, Leuraud P, Marie Y, et al.: Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas. Ann Neurol 2002, 52:105–107. This paper show an exclusive paternal loss of 19q, suggesting that the gene involved in oligodendrogliomas on 19q13.3-4 is maternally imprinted.PubMedCrossRefGoogle Scholar
  24. 24.
    Sasaki H, Zlatescu MC, Betensky RA, et al.: PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001, 159:359–367.PubMedGoogle Scholar
  25. 25.
    Sanson M, Leuraud P, Aguirre-Cruz L, et al.: Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg 2002, 97:1397–1401.PubMedGoogle Scholar
  26. 26.
    Hoang-Xuan K, He J, Huguet S, et al.: Molecular heterogeneity of oligodendrogliomas suggest alternative pathways in tumoral progression. Neurology 2001, 57:1278–1281.PubMedGoogle Scholar
  27. 27.
    Kraus JA, Koopmann J, Kaskel P, et al.: Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995, 54:91–95.PubMedGoogle Scholar
  28. 28.
    Maintz D, Fiedler K, Koopmann J, et al.: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997, 56:1098–1104.PubMedGoogle Scholar
  29. 29.
    Yahanda AM, Bruner JM, Donehower LA, Morrison RS: Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol 1995, 15:4249–4259.PubMedGoogle Scholar
  30. 30.
    Cairncross JG, Ueki K, Zlatescu MC, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473–1479.PubMedCrossRefGoogle Scholar
  31. 31.
    Smith JS, Perry A, Borell TJ, et al.: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000, 18:636–640.PubMedGoogle Scholar
  32. 32.
    Bauman GS, Ino Y, Ueki K, et al.: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000, 48:825–830.PubMedCrossRefGoogle Scholar
  33. 33.
    Zlatescu MC, Tehrani Yazdi A, Sasaki H, et al.: Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001, 61:6713–7615.PubMedGoogle Scholar
  34. 34.
    Mueller W, Hartmann C, Hoffmann A, et al.: Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002, 161:313–319.PubMedGoogle Scholar
  35. 35.
    Spassky N, Heydon K, Mangatal A, et al.: Sonic hedgehogdependent emergence of oligodendrocytes in the telencephalon: evidence for a source of oligodendrocytes in the olfactory bulb that is independent of PDGFRalpha signaling. Development 2001, 128:4993–5004.PubMedGoogle Scholar
  36. 36.
    Mukasa A, Ueki K, Matsumoto S, et al.: Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002, 21:3961–3968.PubMedCrossRefGoogle Scholar
  37. 37.
    Watson MA, Perry A, Budhjara V, et al.: Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res 2001, 61:1825–1829.PubMedGoogle Scholar
  38. 38.
    Karim AB, Afra D, Cornu P, et al.: Randomized trial on the efficacy of radiotherapy for cerebral low grade glioma in the adult: EORTC study 22845 with medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002, 52:316–324.PubMedCrossRefGoogle Scholar
  39. 39.
    Karim AB, Maat B, Hatlevoll R, et al.: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 1996, 36:549–556.PubMedCrossRefGoogle Scholar
  40. 40.
    Shaw E, Arussell R, Scheithauer B, et al.: Prospective randomized trial of low versus high dose radiation therapy in adults with supratentorial low grade glioma: initial report of the NCCTG/RTOG/ECOG study. J Clin Oncol 2002, 20:2267–2276.PubMedCrossRefGoogle Scholar
  41. 41.
    Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996, 46:203–207.PubMedGoogle Scholar
  42. 42.
    Buckner J: Primary chemotherapy (PCV) in low grade glioma phase II trial [abstract]. J Neuro-Oncol 1999, 35:S12.Google Scholar
  43. 43.
    Soffietti R: PCV chemotherapy for newly diagnosed low grade oligodendroglial tumors: a phase II study [abstract]. Neurooncology 2001, 34:400.Google Scholar
  44. 44.
    Viviers L: A phase II trial of primary chemotherapy with temozolomide in patients with low grade gliomas. Neuro-oncology 2000, 2(suppl 1):S43.Google Scholar
  45. 45.
    Olson JD, Riedel E, DeAngelis LM: Long term outcome of low grade oligodendroglioma and mixed glioma. Neurology 2000, 54:1442–1448.PubMedGoogle Scholar
  46. 46.
    Walker MD, Alexander E Jr, Hunt WF, et al.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333–343.PubMedCrossRefGoogle Scholar
  47. 47.
    Fortin D, Cairncross G, Hammond RR: Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999, 45:1279–1291.PubMedCrossRefGoogle Scholar
  48. 48.
    Glass J, Hochberg FH, Gruber ML, et al.: The treatment of oligodendrogliomas and mixed oligodendrogliomas with PCV chemotherapy. J Neurosurg 1992, 76:741–745.PubMedGoogle Scholar
  49. 49.
    Cairncross G, Macdonald D, Ludwin S, et al.: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994, 12:2013–2021.PubMedGoogle Scholar
  50. 50.
    Kim L, Hochberg FH, Thornton AF, et al.: PCV chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 1996, 85:602–607.PubMedCrossRefGoogle Scholar
  51. 51.
    Soffietti R, Ruda R, Bradac GB, Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998, 43:1066–1073.PubMedCrossRefGoogle Scholar
  52. 52.
    Van den Bent MJ, Kros JM, Heimans JJ, et al.: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology 1998, 51:1140–1145.PubMedGoogle Scholar
  53. 53.
    Streffer J, Schabet M, Bamberg M, et al.: A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurol 2000, 247:297–302.PubMedCrossRefGoogle Scholar
  54. 54.
    Chinot OL, Honoré S, Dufour H, et al.: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001, 19:2449–2445. This paper reports a high response rate (44%) in patients with recurrent anaplastic oligodendrogliomas treated with temozolomide after failure of PCV regimen.PubMedGoogle Scholar
  55. 55.
    Van den Bent MJ, Keime-Guibert F, Brandes AA, et al.: Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001, 57:340–342. This paper reports a high response rate (26%) in patients with recurrent anaplastic oligodendrogliomas treated with temozolomide after failure of PCV regimen.PubMedGoogle Scholar
  56. 56.
    Shaw EG, Scheithauer BW, O’Fallon JR: Supratentorial gliomas: a comparative study by grade and histologic type. J Neuro-Oncol 1997, 31:273–278.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Marc Sanson
    • 1
  • Lucinda Aguirre-Cruz
    • 1
  • Stéphanie Cartalat-Carel
    • 1
  • Khe Hoang-Xuan
    • 1
  1. 1.Inserm U495 and Fédération de Neurologie MazarinHopital de la SalpetriéreParisFrance

Personalised recommendations